Judy Sing-Zan Wang

Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of <i>WT p53</i> in patients with solid tumors and lymphomas.

Funda Meric‐Bernstam, Mansoor N. Saleh, Jeffrey R. Infante et al. · Journal of Clinical Oncology · 2017 · 78 citations

Tp53 Wild-type, Solid Tumors, Immunology +21

Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.

Manish R. Patel, Gerald S. Falchook, Judy Sing-Zan Wang et al. · Journal of Clinical Oncology · 2019 · 29 citations

Immunology, Pathology, Pharmacotherapy +18

First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data.

Judy Sing-Zan Wang, Serena De Vita, Janet L. Karlix et al. · Journal of Clinical Oncology · 2019 · 23 citations

Immunology, Pathology, Small Molecule Inhibitor +22

BT5528-100 phase I/II study of the safety, pharmacokinetics, and preliminary clinical activity of BT5528 in patients with advanced malignancies associated with EphA2 expression.

Johanna C. Bendell, Judy Sing-Zan Wang, Babar Bashir et al. · Journal of Clinical Oncology · 2020 · 16 citations

Immunology, Immunoediting, Pathology +19

A phase Ib study of AZD1775 and olaparib combination in patients with refractory solid tumors.

Erika Hamilton, Judy Sing-Zan Wang, Gerald S. Falchook et al. · Journal of Clinical Oncology · 2016 · 12 citations

Surgical Oncology, Olaparib Results, Surgery +20